Delphia (Usa) Inc. Fate Therapeutics Inc Transaction History

Delphia (Usa) Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $12,771 - $21,888	-607 Reduced 6.14%	9,272 $208,000
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $70,248 - $167,482	3,951 Added 66.65%	9,879 $245,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $175,883 - $357,339	5,928 New	5,928 $230,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

Stay updated on Delphia (Usa) Inc. with notifications on news.